Submitter: Olympus Terumo Biomaterials Corp.

FOUNDATION Traditional 510(k)

## Section 5.0 510(k) Summary

NOV 2 9 2011

Submitter Name:

Olympus Terumo Biomaterials Corporation

Submitter Address:

Shinjuku Monolith

3-1 Nishi-Shinjuku 2-chome

Shinjuku-ku

Tokyo, Japan 163-0914

Contact Person:

Laura Storms-Tyler, US Agent

Telephone Number

484-896-5688

for US Agent:

Date Prepared:

**Device Trade Name:** 

FOUNDATION

August 25, 2011

Classification Name

and Number:

Bone grafting material 21 CFR 872.3930

Class:

2

**Product Code** 

LYC

Common Name:

Bone grafting material, synthetic

Predicate Device:

FOUNDATION, Terumo Corporation, K040783

Statement of Intended Use: The FOUNDATION device is a collagen-based bone filling augmentation material for use in filling of extraction sockets.

Device Description. Summary of Technological

The FOUNDATION bone filler device is a sponge-like absorbable

natural collagen plug designed to be used as indicated.

FOUNDATION consists of approximately 85-95% Type I collagen and approximately 5-15% Type III collagen from bovine dermis.

Comparison to the **Predicate Device** 

Characteristics

The FOUNDATION is available as a bullet shape in three sizes (in mm: 8x15, 8x25, 15x25) and a sheet type in two sizes (mm: 25x25 and 50x25). The device is provided sterile, for single use in a heat-

sealed aluminum package.

The FOUNDATION is substantially equivalent to its parent FOUNDATION predicate device in the raw material source and type of collagen, in device design, and in product forms and sizes:

Conclusion regarding Substantial Equivalence

The difference in the country source for the bovine raw material is the purpose for submitting this 510(k). Appropriate controls and validations assure there is no effect on the safety, performance, and thus substantial equivalence of the new FOUNDATION

compared to the predicate.







Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

Olympus Terumo Biomaterials Corporation C/O Ms. Patsy J. Trisler Regulatory Consultant Trisler Consulting 5600 Wisonsin Avenue, # 509 Chevy Chase, Maryland 20815

NOV 2 9 2011

Re: K111087

Trade/Device Name: Foundation Regulation Number: 21 CFR 872.3930 Regulation Name: Bone Grafting Material

Regulatory Class: II Product Code: LYC Dated: October 24, 2011 Received: October 27, 2011

## Dear Ms. Trisler:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <a href="http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/">http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices//ucm115809.htm</a> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm</a> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

Sincerely yours,

Anthony D. Watson, B.S., M.S., M.B.A.

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and

Radiological Health

510(k) Number (if known):	K11 10	<u>87</u>
Device Name:	Foundation	
Indications for Use:		
The FOUNDATION device is use in filling of extraction sock	a collagen-based ets.	d bone filling augmentation material for
Prescription Use <u>x</u> (Part 21 CFR 801 Subpart D)	AND/OR	Over-The-Counter Use(21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BEL	OW THIS LINE-C NEEDED)	ONTINUE ON ANOTHER PAGE IF
	remove at the same	en en seus de seus de la company de seus de la company
Concurrence of CI	ORH, Office of Dev	rice Evaluation (ODE)
•		
(Posted November 13, 2003)		
	š	Sugar
	•	Division Sign-Off)
		vision of Anesthesiology, General Hospital

510(k) Number: KILIOR7